It's time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
The "Talking Squawk" blog is meant to be a funny, sarcastic look at business news through the unique "Squawk Box" lens. But it was difficult to think about anything from that viewpoint this week.
LONDON, April 19- Japan's Astellas Pharma and Britain's GlaxoSmithKline are competing to develop a new kind of medicine that boosts production of red blood cells by making the body think it is at high altitude.
It seems like that historic high for the S&P 500 was 5 years ago, but it's not. We're only 3.5 percent off the historic high in the S&P 500, which occurred exactly one week ago.
Some of the names on the move ahead of the open.
Check out which companies are making headlines after the bell Tuesday:
Deflationary winds? Traders are fixing on the idea of deflationary fears as the main reason commodities and commodity stocks are down so much.
Some cancers could be cured within the next couple of years, Celgene CEO Robert Hugin told CNBC.
April 7- U.S. drugmaker Bristol-Myers Squibb Co said on Sunday it has named Francis Cuss to become its next chief scientific officer after Elliott Sigal retires as head of research and development on June 30. He joined Bristol-Myers in 2003 after spending 14 years working at Schering-Plough and three with British drugmaker GlaxoSmithKline.
Take a look at some of Tuesday's midday movers:
ZURICH, March 25- Delays in developing copies of Roche's top-selling biotech drug are justifying the Swiss company's decision to stay out of biotech generics to focus on improved, patented versions of its medicines.
NEW YORK, March 20- A U.S. judge certified on Wednesday a class of investors who have filed a lawsuit accusing Sanofi of misleading them about the status of regulatory approval for a failed anti-obesity pill. District Judge George Daniels in Manhattan said investors in Sanofi's American depositary receipts could proceed together as a group in the litigation.
March 19- Amgen Inc said its experimental and novel treatment for advanced melanoma met the main goal of a late-stage clinical trial by demonstrating a durable response in significantly more patients than a comparison treatment.
WASHINGTON, March 19- The U.S. Supreme Court on Tuesday ruled that a homeowner seeking to sue his insurer could not file suit in a state court considered friendly to plaintiffs. Greg Knowles, whose house had sustained hail damage, accused Travelers Cos' Standard Fire Insurance Co unit of refusing to pay the cost of hiring general contractors.
March 7- Merck& Co will bring back one of its veterans to head research and development, replacing retiring Peter Kim, who leaves behind a mixed record over the past decade at the drugmaker's highly respected laboratories.
The "Fast Money" traders name a few stocks to buy on a pullback.
DUBLIN, March 4- Irish drugmaker Elan has sweetened the terms on offer to shareholders under its $3.25 billion disposal plan, as it aims to stave off an approach for the company from U.S. investment firm Royalty Pharma.
March 2- Celgene Corp's experimental drug apremilast proved to be more effective than a dummy pill for psoriasis patients in a late-stage study, clearing the way for the company to file for U.S. regulatory approval in the second half of 2013..
*Amgen shares rise over 1 pct in afternoon trading. By a 6-3 vote, the court allowed shareholders of Amgen Inc to sue the biotechnology company as a group without first having to show that misinformation had materially and fraudulently inflated its stock price.
The decision by the court was in a case brought against biotechnology firm Amgen Inc over what kind of evidence must be presented before companies may be the subject of class-action lawsuits.
WASHINGTON, Feb 27- The U.S. Supreme Court made it easier on Wednesday to bring class action lawsuits, breaking a line of rulings that had made it more difficult to sue corporate defendants collectively and perhaps obtain greater recoveries.